GM1 Gangliosidosis Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The GM1 Gangliosidosis Market By 2029?

The gm1 gangliosidosis market size has shown swift growth in recent years. It is anticipated to expand from $0.51 billion in 2024 to $0.57 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.1%. The expansion observed in the past can be attributed to an increase in the number of patients afflicted with gm1 gangliosidosis, a broadening area of focus within the gm1 gangliosidosis sector, the rising prevalence of rare disease awareness, the growing popularity of patient-centric research, and a heightened emphasis on early intervention.

The gm1 gangliosidosis market is anticipated to experience substantial growth over the next few years. It is projected to reach $0.87 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period can be attributed to factors such as an increase in gm1 gangliosidosis cases, a rise in lysosomal storage disorders, an expanding number of clinical trials, a heightened focus on gene therapy and editing, the progression of personalized and precision medicine, and increased adoption of genetic screening programs. Prominent trends expected in this period include advancements in gene-editing technologies, greater integration of technology within healthcare, improvements in diagnostic techniques, the development of advanced formulations, and breakthroughs in genetic therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The GM1 Gangliosidosis Industry?

The expanding implementation of gene therapy is projected to boost the GM1 gangliosidosis market’s expansion moving forward. Gene therapy is a medical intervention focused on modifying or substituting genes within individual cells to address or prevent illnesses. This rising acceptance of gene therapy stems from progress in genetic research, enhanced therapeutic results for conditions previously without effective treatments, and increasing regulatory backing for novel therapies. In the context of GM1 gangliosidosis, gene therapy entails delivering a working version of the faulty gene (GLB1) into patient cells to reinstate β-galactosidase enzyme activity and diminish the accumulation of toxic substrates. As an illustration, in April 2024, data from the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, indicated that in the fourth quarter, phase III gene therapy clinical trials saw a 10% increase, representing the first quarterly rise since the third quarter of 2022. Consequently, the growing integration of gene therapy is propelling the growth of the GM1 gangliosidosis market.

What Are The Segment Types Shaping The GM1 Gangliosidosis Market?

The gm1 gangliosidosismarket covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis; Type 2 GMT Gangliosidosis; Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants; Bone Marrow Transplantation; Cord-Blood Hematopoietic Stem-Cell Transplantation; Enzyme Replacement; Gene Therapy

3) By End-User: Research Institutes; Hospitals; Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset; Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset; Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset; Atypical Adult Onset

Which Market Trends Are Creating New Opportunities In The GM1 Gangliosidosis Industry?

Leading firms involved in the GM1 gangliosidosis market are prioritizing collaborative alliances to maintain their competitive standing. These alliances are vital for progressing gene therapy development, as they merge specialized knowledge, assets, and innovative tools to hasten discovery, clinical testing, and market introduction. As an illustration, in October 2024, GEMMA Biotherapeutics Inc., a biotechnology firm located in the US, formed a partnership with the Oswaldo Cruz Foundation (Fiocruz), a health research body situated in Brazil, with the goal of creating gene therapies for uncommon illnesses, such as GM1 gangliosidosis. This agreement entails financial backing of up to $100 million from Fiocruz, designated for clinical investigation and production, with the intent of making these innovative treatments available via Brazil’s governmental healthcare framework. This joint effort highlights the transfer of technology and seeks to broaden the availability of therapies that were formerly exclusive to wealthier populations.

Which Industry Leaders Are Driving Innovation Across The GM1 Gangliosidosis Market?

Major companies operating in the GM1 gangliosidosis market are Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc., CRISPR Therapeutics AG, REGENXBIO Inc., Passage Bio Inc., Orchard Therapeutics plc, AVROBIO Inc., uniQure N.V., GEMMA Biotherapeutics Inc., Lysogene S.A., AZAFAROS B.V., BioStrategies LC, Sio Gene Therapies Inc., Gain Therapeutics Inc., Dorphan S.A., bluebird bio Inc., Axovant Gene Therapies Ltd., SphinCS GmbH.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

How Is GM1 Gangliosidosis Market Demand Varying Across Different Regions?

North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The GM1 Gangliosidosis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp

Browse Through More Reports Similar to the Global GM1 Gangliosidosis Market 2025, By The Business Research Company

Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Epigenetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/epigenetics-global-market-report

Direct To Consumer Dtc Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/direct-to-consumer-dtc-genetic-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795